D015 Aldosterone plays a pro-angiogenic role by enhancing VEGF-A production in immune cells - 17/04/09
Résumé |
Background and aim |
VEGF-A has been described to be an important pro-angiogenic factor. Immune cells are intimately involved in tissue repair and neovascularisation notably by their capacity to secrete VEGF-A. Moreover, these cells possess mineralocorticoid receptors. The present study was designed to investigate whether aldosterone (Aldo) was able to regulate VEGF-A production of immune cells.
Methods |
HL-60 (progranulocytic) and THP-1 (promonocytic) cell lines and human blood neutrophils and monocytes were incubated for different times with Aldo (10-7, 10-8, 10-9 M). Total cellular RNA extraction, submitted to reverse transcription and real time quantitative PCR was used to study VEGF-A mRNA expression. Cell supernatants were collected and ELISA tests were performed to analyse VEGF-A protein excretion.
Results |
All four cell types increased their VEGF-A mRNA and protein production. VEGF-A mRNA expression increased from 30 mn and time for maximal expression depended on cell type: 30 mn for HL-60 and THP-1 cells, and for blood neutrophils3 hours after Aldo addition. ELISA tests showed increased excretion of VEGF-A proteins after 24 hours of Aldo contact for all four cell types. Western-blotting performed with HL-60 and THP-1 cells showed that ERK1/2 and p38 pathways are stimulated by Aldo. ERK1/2, p38 and PI3kinase transduction signal inhibitors decreased this immune cell activation orchestrated by Aldo.
Conclusion |
We have demonstrated that Aldo is able to increase VEGF-A production of phagocytic cells such as neutrophils and monocytes. This phenomenon is PI3K, ERK1/2 and p38 dependent. These cells play an important role in tissue healing notably by their capacity to degrade dead cells and to secrete pro-angiogenic factors such as VEGF-A in situ. It appears that Aldo could play an important role in this neovascularisation process by favouring cell proliferation and tissue building.
Le texte complet de cet article est disponible en PDF.Vol 102 - N° S1
P. S41 - mars 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.